Accelerating Patients' Access to Advanced Therapies in the EU.

about

The involvement of Canadian physicians in promoting and providing unproven and unapproved stem cell interventions.Concise Review: A Comprehensive Analysis of Reported Adverse Events in Patients Receiving Unproven Stem Cell-Based Interventions

P2860

Q55259610-F26096F3-9ECB-4942-9F82-E5600E1CB04F Q56965233-647F3684-E20D-4875-A577-775BA2D027B3

P2860

Accelerating Patients' Access to Advanced Therapies in the EU.

Item

http://www.wikidata.org/entity/Q42362633

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Accelerating Patients' Access to Advanced Therapies in the EU.

@en

Accelerating Patients' Access to Advanced Therapies in the EU.

@nl

type

Item

label

Accelerating Patients' Access to Advanced Therapies in the EU.

@en

Accelerating Patients' Access to Advanced Therapies in the EU.

@nl

prefLabel

Accelerating Patients' Access to Advanced Therapies in the EU.

@en

Accelerating Patients' Access to Advanced Therapies in the EU.

@nl

P1476

Accelerating Patients' Access to Advanced Therapies in the EU.

@en

P2093

Ahmed Elsanhoury

http://www.w3.org/2001/XMLSchema#string

Ralf Sanzenbacher

http://www.w3.org/2001/XMLSchema#string

P2860

Access to Orphan Drugs: A Comprehensive Review of Legislations, Regulations and Policies in 35 Countries

Display technologies: application for the discovery of drug and gene delivery agents.

Proceedings: international regulatory considerations on development pathways for cell therapies.

A roadmap toward clinical translation of genetically-modified stem cells for treatment of HIV.

Regulation of Clinical Trials with Advanced Therapy Medicinal Products in Germany.

Overcoming Challenges Facing Advanced Therapies in the EU Market.

Engineered T cells: the promise and challenges of cancer immunotherapy.

A comprehensive map of molecular drug targets.

The European hospital exemption clause-new option for gene therapy?

The need for increased clarity and transparency in the regulatory pathway for gene medicines in the European Union.

P304

15-19

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.OMTM.2017.08.005

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Mohamed Abou El-Enein

Petra Reinke

P577

2017-09-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28971109

http://www.w3.org/2001/XMLSchema#string

P932

5609878

http://www.w3.org/2001/XMLSchema#string

Accelerating Patients' Access to Advanced Therapies in the EU.

about

P2860

P2860

Accelerating Patients' Access to Advanced Therapies in the EU.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P478

P50

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P478

P50

P577

P698

P932